CD274 and small cell lung carcinoma: The Moffitt cohort consisted of 13 relapsed SCLC patients treated with anti-PD-1 (nivolumab) or anti-PD-L1 (durvalumab) therapy with or without anti-CTLA-4 antibodies (ipilimumab or tremelimumab) (Supplementary Figs. 7 and 8, Supplementary Data 15).